Recent Articles in Cell & Gene Therapy

Beijing CorreGene Biotechnology completed $14 million Pre-A+ financing round to develop new cancer drug using its cutting-edge T-cell receptor (TCR-T) platform. The company says TCR-T can target almost all proteins expressed by tumor cells while CAR-T drugs are limited to targeting antigens expressed on the surface of tumor cells. The platform re-engineers patients’ T cells with optimized TCR. CorreGene has two candidates in early-stage clinical trials. The round was co-led by Riverhead Capital and Xinrui Investment and included Longmen Capital. More details....

Share this with colleagues:  

Shanghai JW Therapeutics will partner with Boston’s 2seventy bio to use 2seventy’s cell therapy platform to develop T cell-based immunotherapies for Greater China. The collaboration will focus initially on 2seventy bio’s MAGE-A4 TCR program in solid tumors. JW will be responsible for development, manufacturing, and commercialization within China. 2seventy bio will receive milestones and royalty payments on revenues in China, and 2seventy may use JW’s clinical data to support ex-China development. Financial details of the agreement were not disclosed. More details....

Stock Symbols: (HK: 2126) (NSDQ: TSVT)

Share this with colleagues:  

ImmVira, a Shenzhen company that develops next-gen anti-cancer drug vectors, has signed Series-C+ financing documents with the first batch of investors. The company will keep the round open for as long as two months. It told investors that they can also invest at the same terms as those established by the lead investor and ImmVira. The C+ round was led by China Merchants China Direct Investments Limited with Lifebay and Unifortune Group participating. More details....

Share this with colleagues:  

Chicago-based VectorBuilder, a gene therapy delivery CDMO, raised $57 million in a Series C round from China investors. VectorBuilder develops and optimizes gene delivery products for research institutions and pharma companies. Earlier this year, VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. The C round was co-led by Legend Capital, Suikai Investment (55% owned by state-owned firm Guangzhou Development District Investment Group) and Yuexiu Industrial Fund, a PE investor. More details....

Share this with colleagues:  

Hangzhou Celgenyx completed a $14 million Series A Round to support development of its off-the-shelf cell therapies, either through partnerships or its own R&D. All of the capital was contributed by Vivo Partners from an RMB fund. Hangzhou Celgenyx is a development-stage biotech, dedicated to the acquisition and development of next-gen cell immunotherapies for malignant cancers. Celgenyx expects to complete construction of a 3000 square meter R&D center and GMP pilot production base in Hangzhou before the end of 2022. More details....

Share this with colleagues: